Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Autor: Gerhard C. Hildebrandt, Mehdi Hamadani, Parastoo B. Dahi, Praveen Ramakrishnan, Tim Prestidge, Lazaros J. Lekakis, Bradley M. Haverkos, Kwang Woo Ahn, Minoo Battiwalla, Attaphol Pawarode, Farhad Khimani, Taiga Nishihori, Ana Sureda, Alex F. Herrera, Cesar O. Freytes, Sunita Nathan, David J. Inwards, Umar Farooq, Nirav N. Shah, Nilanjan Ghosh, Andrew R. Rezvani, Timothy S. Fenske, Sairah Ahmed, Hillard M. Lazarus, Carlos Litovich, Mark P. Hertzberg, Hemant S. Murthy, Narendranath Epperla, Nosha Farhadfar, Aleksandr Lazaryan, Mohamed A. Kharfan-Dabaja, Jonathon B. Cohen, Rizwan Romee
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
GVL effects
Male
Cancer Research
Transplantation Conditioning
Graft vs Host Disease
Gastroenterology
0302 clinical medicine
Risk of mortality
Cumulative incidence
Registries
Autografts
Aged
80 and over
Hematology
Angioimmunoblastic T-cell lymphoma
Hematopoietic Stem Cell Transplantation
lcsh:Diseases of the blood and blood-forming organs
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Progression-Free Survival
3. Good health
surgical procedures
operative
Oncology
030220 oncology & carcinogenesis
Female
Adult
medicine.medical_specialty
Allogeneic transplantation
Lymphoma
T-Cell
lcsh:RC254-282
Transplantation
Autologous
03 medical and health sciences
Young Adult
Internal medicine
medicine
Humans
Transplantation
Homologous
Molecular Biology
Aged
Salvage Therapy
business.industry
lcsh:RC633-647.5
Research
medicine.disease
Lymphoma
Transplantation
Calcineurin
030104 developmental biology
Drug Resistance
Neoplasm
business
Follow-Up Studies
Zdroj: Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-11 (2019)
ISSN: 1756-8722
Popis: Background There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL patients undergoing an allo-HCT. Methods We evaluated 249 adult AITL patients who received their first allo-HCT during 2000–2016. Results The median patient age was 56 years (range = 21–77). Majority of the patients were Caucasians (86%), with a male predominance (60%). Graft-versus-host disease (GVHD) prophylaxis was predominantly calcineurin inhibitor-based approaches while the most common graft source was peripheral blood (97%). Median follow-up of survivors was 49 months (range = 4–170 months). The cumulative incidence of grade 2–4 and grade 3–4 acute GVHD at day 180 were 36% (95% CI = 30–42) and 12 (95% CI = 8–17), respectively. The cumulative incidence of chronic GVHD at 1 year was 49% (95%CI 43–56). The 1-year non-relapse mortality (NRM) was 19% (95% CI = 14–24), while the 4-year relapse/progression, progression-free survival (PFS), and overall survival (OS) were 21% (95% CI = 16–27), 49% (95% CI = 42–56), and 56% (95% CI = 49–63), respectively. On multivariate analysis, chemoresistant status at the time of allo-HCT was associated with a significantly higher risk for therapy failure (inverse of PFS) (RR = 1.73 95% CI = 1.08–2.77), while KPS
Databáze: OpenAIRE
Externí odkaz: